Id: acc2552
Group: 1sens
Protein: mTORC1
Gene Symbol: MTOR
Protein Id: P42345
Protein Name: MTOR_HUMAN
PTM: phosphorylation
Site: Thr172
Site Sequence: GRRHAAVLVLRELAISVPTFF
Disease Category: Cancer
Disease: Myeloma
Disease Subtype: multiple myeloma
Disease Cellline:
Disease Info:
Drug: metformin
Drug Info: "Metformin is an oral antihyperglycemic agent used primarily in the treatment of type 2 diabetes, which works by reducing hepatic glucose production and enhancing peripheral insulin sensitivity."
Effect: inhibit
Effect Info: Ritonavir enhances the sensitivity of multiple myeloma cells to metformin through phosphorylation inhibition.
Note:
Score: 5.0
Pubmed(PMID): 25542900
Sentence Index:
Sentence:

Sequence & Structure:

MLGTGPAAATTAATTSSNVSVLQQFASGLKSRNEETRAKAAKELQHYVTMELREMSQEESTRFYDQLNHHIFELVSSSDANERKGGILAIASLIGVEGGNATRIGRFANYLRNLLPSNDPVVMEMASKAIGRLAMAGDTFTAEYVEFEVKRALEWLGADRNEGRRHAAVLVLRELAISVPTFFFQQVQPFFDNIFVAVWDPKQAIREGAVAALRACLILTTQREPKEMQKPQWYRHTFEEAEKGFDETLAKEKGMNRDDRIHGALLILNELVRISSMEGERLREEMEEITQQQLVHDKYCKDLMGFGTKPRHITPFTSFQAVQPQQSNALVGLLGYSSHQGLMGFGTSPSPAKSTLVESRCCRDLMEEKFDQVCQWVLKCRNSKNSLIQMTILNLLPRLAAFRPSAFTDTQYLQDTMNHVLSCVKKEKERTAAFQALGLLSVAVRSEFKVYLPRVLDIIRAALPPKDFAHKRQKAMQVDATVFTCISMLARAMGPGIQQDIKELLEPMLAVGLSPALTAVLYDLSRQIPQLKKDIQDGLLKMLSLVLMHKPLRHPGMPKGLAHQLASPGLTTLPEASDVGSITLALRTLGSFEFEGHSLTQFVRHCADHFLNSEHKEIRMEAARTCSRLLTPSIHLISGHAHVVSQTAVQVVADVLSKLLVVGITDPDPDIRYCVLASLDERFDAHLAQAENLQALFVALNDQVFEIRELAICTVGRLSSMNPAFVMPFLRKMLIQILTELEHSGIGRIKEQSARMLGHLVSNAPRLIRPYMEPILKALILKLKDPDPDPNPGVINNVLATIGELAQVSGLEMRKWVDELFIIIMDMLQDSSLLAKRQVALWTLGQLVASTGYVVEPYRKYPTLLEVLLNFLKTEQNQGTRREAIRVLGLLGALDPYKHKVNIGMIDQSRDASAVSLSESKSSQDSSDYSTSEMLVNMGNLPLDEFYPAVSMVALMRIFRDQSLSHHHTMVVQAITFIFKSLGLKCVQFLPQVMPTFLNVIRVCDGAIREFLFQQLGMLVSFVKSHIRPYMDEIVTLMREFWVMNTSIQSTIILLIEQIVVALGGEFKLYLPQLIPHMLRVFMHDNSPGRIVSIKLLAAIQLFGANLDDYLHLLLPPIVKLFDAPEAPLPSRKAALETVDRLTESLDFTDYASRIIHPIVRTLDQSPELRSTAMDTLSSLVFQLGKKYQIFIPMVNKVLVRHRINHQRYDVLICRIVKGYTLADEEEDPLIYQHRMLRSGQGDALASGPVETGPMKKLHVSTINLQKAWGAARRVSKDDWLEWLRRLSLELLKDSSSPSLRSCWALAQAYNPMARDLFNAAFVSCWSELNEDQQDELIRSIELALTSQDIAEVTQTLLNLAEFMEHSDKGPLPLRDDNGIVLLGERAAKCRAYAKALHYKELEFQKGPTPAILESLISINNKLQQPEAAAGVLEYAMKHFGELEIQATWYEKLHEWEDALVAYDKKMDTNKDDPELMLGRMRCLEALGEWGQLHQQCCEKWTLVNDETQAKMARMAAAAAWGLGQWDSMEEYTCMIPRDTHDGAFYRAVLALHQDLFSLAQQCIDKARDLLDAELTAMAGESYSRAYGAMVSCHMLSELEEVIQYKLVPERREIIRQIWWERLQGCQRIVEDWQKILMVRSLVVSPHEDMRTWLKYASLCGKSGRLALAHKTLVLLLGVDPSRQLDHPLPTVHPQVTYAYMKNMWKSARKIDAFQHMQHFVQTMQQQAQHAIATEDQQHKQELHKLMARCFLKLGEWQLNLQGINESTIPKVLQYYSAATEHDRSWYKAWHAWAVMNFEAVLHYKHQNQARDEKKKLRHASGANITNATTAATTAATATTTASTEGSNSESEAESTENSPTPSPLQKKVTEDLSKTLLMYTVPAVQGFFRSISLSRGNNLQDTLRVLTLWFDYGHWPDVNEALVEGVKAIQIDTWLQVIPQLIARIDTPRPLVGRLIHQLLTDIGRYHPQALIYPLTVASKSTTTARHNAANKILKNMCEHSNTLVQQAMMVSEELIRVAILWHEMWHEGLEEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRRISKQLPQLTSLELQYVSPKLLMCRDLELAVPGTYDPNQPIIRIQSIAPSLQVITSKQRPRKLTLMGSNGHEFVFLLKGHEDLRQDERVMQLFGLVNTLLANDPTSLRKNLSIQRYAVIPLSTNSGLIGWVPHCDTLHALIRDYREKKKILLNIEHRIMLRMAPDYDHLTLMQKVEVFEHAVNNTAGDDLAKLLWLKSPSSEVWFDRRTNYTRSLAVMSMVGYILGLGDRHPSNLMLDRLSGKILHIDFGDCFEVAMTREKFPEKIPFRLTRMLTNAMEVTGLDGNYRITCHTVMEVLREHKDSVMAVLEAFVYDPLLNWRLMDTNTKGNKRSRTRTDSYSAGQSVEILDGVELGEPAHKKTGTTVPESIHSFIGDGLVKPEALNKKAIQIINRVRDKLTGRDFSHDDTLDVPTQVELLIKQATSHENLCQCYIGWCPFW

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
MTOR PERHEXILINE Serine/threonine-protein kinase mTOR inhibitor 4 - cardiovascular disease ATC
MTOR PERHEXILINE Serine/threonine-protein kinase mTOR inhibitor 3 Withdrawn hypertrophic cardiomyopathy ClinicalTrials
MTOR DACTOLISIB Serine/threonine-protein kinase mTOR inhibitor 3 Completed infection ClinicalTrials
MTOR RIDAFOROLIMUS Serine/threonine-protein kinase mTOR inhibitor 3 - neoplasm ATC
MTOR RIDAFOROLIMUS Serine/threonine-protein kinase mTOR inhibitor 3 Completed soft tissue sarcoma ClinicalTrials
MTOR GEDATOLISIB Serine/threonine-protein kinase mTOR inhibitor 3 Recruiting breast cancer ClinicalTrials
MTOR RIDAFOROLIMUS Serine/threonine-protein kinase mTOR inhibitor 3 Completed bone sarcoma ClinicalTrials
MTOR SF-1126 Serine/threonine-protein kinase mTOR inhibitor 2 Terminated head and neck squamous cell carcinoma ClinicalTrials
MTOR ONATASERTIB Serine/threonine-protein kinase mTOR inhibitor 2 Terminated hepatocellular carcinoma ClinicalTrials
MTOR INDOXIMOD mTORC1 activator 2 Completed metastatic prostate cancer ClinicalTrials
MTOR RIDAFOROLIMUS Serine/threonine-protein kinase mTOR inhibitor 2 Completed myelodysplastic syndrome ClinicalTrials
MTOR GEDATOLISIB Serine/threonine-protein kinase mTOR inhibitor 2 Terminated myelodysplastic syndrome ClinicalTrials
MTOR GEDATOLISIB Serine/threonine-protein kinase mTOR inhibitor 2 Terminated acute myeloid leukemia ClinicalTrials
MTOR SAPANISERTIB Serine/threonine-protein kinase mTOR inhibitor 2 Active, not recruiting T-cell acute lymphoblastic leukemia ClinicalTrials
MTOR VISTUSERTIB Serine/threonine-protein kinase mTOR inhibitor 2 Active, not recruiting adenocarcinoma ClinicalTrials
MTOR VISTUSERTIB Serine/threonine-protein kinase mTOR inhibitor 2 Terminated clear cell renal carcinoma ClinicalTrials
MTOR VISTUSERTIB Serine/threonine-protein kinase mTOR inhibitor 2 Terminated gastric adenocarcinoma ClinicalTrials
MTOR PERHEXILINE Serine/threonine-protein kinase mTOR inhibitor 2 Terminated hypertrophic cardiomyopathy ClinicalTrials
MTOR RIDAFOROLIMUS Serine/threonine-protein kinase mTOR inhibitor 2 Completed leiomyosarcoma ClinicalTrials
MTOR DACTOLISIB Serine/threonine-protein kinase mTOR inhibitor 2 Active, not recruiting infection ClinicalTrials
MTOR RIDAFOROLIMUS Serine/threonine-protein kinase mTOR inhibitor 2 Completed lymphoma ClinicalTrials
MTOR VOXTALISIB Serine/threonine-protein kinase mTOR inhibitor 2 Completed lymphoma ClinicalTrials
MTOR PERHEXILINE Serine/threonine-protein kinase mTOR inhibitor 2 Completed hypertrophic cardiomyopathy ClinicalTrials
MTOR PERHEXILINE Serine/threonine-protein kinase mTOR inhibitor 2 Recruiting hypertrophic cardiomyopathy ClinicalTrials
MTOR RIDAFOROLIMUS Serine/threonine-protein kinase mTOR inhibitor 2 Completed leukemia ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

LAMTOR1-Ser26
Cancer Intensity
BRCA
COAD
HGSC 1.845
ccRCC -0.597
GBM -1.093
HNSC -0.132
LUAD 0.104
LUSC
non_ccRCC
PDAC
UCEC -0.127
LAMTOR1-Ser27
Cancer Intensity
BRCA
COAD 0.43
HGSC 1.255
ccRCC 0.561
GBM -0.93
HNSC
LUAD -1.876
LUSC 1.123
non_ccRCC -0.49
PDAC -0.168
UCEC 0.095
LAMTOR1-Ser42
Cancer Intensity
BRCA
COAD -0.514
HGSC 1.958
ccRCC -0.313
GBM -0.846
HNSC 0.01
LUAD
LUSC
non_ccRCC
PDAC
UCEC -0.294
LAMTOR1-Ser45
Cancer Intensity
BRCA
COAD
HGSC 0.93
ccRCC -1.39
GBM 0.448
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.012
LAMTOR1-Ser56
Cancer Intensity
BRCA
COAD 0.128
HGSC 0.887
ccRCC
GBM
HNSC 0.41
LUAD
LUSC
non_ccRCC
PDAC -1.425
UCEC
LAMTOR1-Ser63
Cancer Intensity
BRCA
COAD 0.037
HGSC -1.018
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.981
LAMTOR1-Ser69
Cancer Intensity
BRCA
COAD
HGSC -0.707
ccRCC 0.707
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
LAMTOR1-Ser73
Cancer Intensity
BRCA
COAD
HGSC -0.707
ccRCC
GBM
HNSC
LUAD 0.707
LUSC
non_ccRCC
PDAC
UCEC
LAMTOR1-Ser98
Cancer Intensity
BRCA
COAD -0.738
HGSC 1.741
ccRCC 0.592
GBM 0.016
HNSC -1.316
LUAD 0.238
LUSC -0.534
non_ccRCC
PDAC
UCEC
LAMTOR1-Thr30
Cancer Intensity
BRCA
COAD -0.707
HGSC 0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
LAMTOR1-Thr48
Cancer Intensity
BRCA -0.801
COAD -0.051
HGSC
ccRCC 0.377
GBM
HNSC -0.711
LUAD -0.263
LUSC -0.615
non_ccRCC 2.064
PDAC
UCEC
LAMTOR1-Tyr40
Cancer Intensity
BRCA
COAD
HGSC 0.514
ccRCC 1.011
GBM 0.093
HNSC -1.138
LUAD 0.832
LUSC
non_ccRCC
PDAC
UCEC -1.311
LAMTOR5-Ser108
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC 1.07
LUAD
LUSC
non_ccRCC -0.159
PDAC
UCEC -0.911
LAMTOR5-Ser99
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.021
GBM
HNSC
LUAD 0.52
LUSC
non_ccRCC -1.391
PDAC
UCEC 0.892
LAMTOR5-Thr106
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.86
GBM
HNSC 0.912
LUAD -0.871
LUSC
non_ccRCC
PDAC
UCEC 0.819
MTOR-Ser1261
Cancer Intensity
BRCA
COAD -0.465
HGSC 2.522
ccRCC -0.319
GBM -0.598
HNSC -0.808
LUAD 0.156
LUSC -0.184
non_ccRCC 0.799
PDAC -0.601
UCEC -0.503
MTOR-Ser2448
Cancer Intensity
BRCA
COAD -0.707
HGSC 0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
MTOR-Ser2478
Cancer Intensity
BRCA 1.378
COAD 0.388
HGSC
ccRCC 0.311
GBM -0.144
HNSC 0.355
LUAD 0.727
LUSC 0.556
non_ccRCC -0.949
PDAC -0.435
UCEC -2.186
MTOR-Ser2481
Cancer Intensity
BRCA 0.302
COAD -0.364
HGSC 2.451
ccRCC -0.257
GBM 0.596
HNSC -0.341
LUAD -0.327
LUSC 0.493
non_ccRCC -1.381
PDAC -0.206
UCEC -0.964
MTOR-Ser567
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM 0.124
HNSC 0.653
LUAD 0.673
LUSC -1.451
non_ccRCC
PDAC
UCEC
MTOR-Thr1262
Cancer Intensity
BRCA
COAD -0.707
HGSC 0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
MTOR-Tyr2449
Cancer Intensity
BRCA
COAD -0.707
HGSC 0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 2448 A Prostate cancer/carcinoma/adenocarcinoma Phosphorylation 22886792
- - P Synovial sarcoma Phosphorylation 23861137
- - P Ameloblastoma Phosphorylation 22977662
- - P Oesophageal squamous cell carcinoma/oesophageal adenocarcinoma Phosphorylation 22333597
- - P Oesophageal adenocarcinoma Phosphorylation 23162107
- - P Uveal melanoma Phosphorylation 36690663
- - P Pancreatic cancer/carcinoma/adenocarcinoma Phosphorylation 22726648
- - U Cervical cancer Ubiquitination 33396624
- - U Hutchinson-gilford progeria syndrome Acetylation 38267537
S 2448 U Non-small cell lung cancer Phosphorylation 33523588
S 2448 U Liver cancer Phosphorylation 23537100
- - U Non-small cell lung cancer/carcinoma Phosphorylation 23886172
- - U Breast cancer/tumor/carcinoma Phosphorylation 23794518
- - U Prostate cancer/carcinoma/adenocarcinoma Phosphorylation 24062605
- - U Gastric cancer Phosphorylation 24030871
- - U Esophageal squamous cell carcinoma Phosphorylation 22944293
- - U Hepatocellular carcinoma Phosphorylation 36809979
- - U Chronic myelogenous leukemia/chronic myeloid leukemia Phosphorylation 23384908
- - U Esophageal squamous cell carcinoma Phosphorylation 23291985
S 2481 U Breast cancer/tumor/carcinoma Phosphorylation 19956839
S 2481 U Breast cancer Phosphorylation 27721400
S 2448 U Pancreatic cancer/carcinoma/adenocarcinoma Phosphorylation 21474066
S 2448 U Ovarian cancer Phosphorylation 15208673
S 2448 U Head and neck squamous cell carcinoma Phosphorylation 21281788
S 2448 U Granulomatosis with polyangiitis Phosphorylation 37720230
S 2448 U Cervical squamous cell cancer Phosphorylation 19079619
S 2448 U Breast cancer Phosphorylation 36797347
S 1261 U Parkinson's disease Phosphorylation 36870058
S 2448 U Adrenocortical carcinoma Phosphorylation 20484036
- - U Hepatocellular carcinoma Glycosylation 36495345

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: